{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:24:31Z","timestamp":1790166271426,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T00:00:00Z","timestamp":1390176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T00:00:00Z","timestamp":1390176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/leu.2014.38","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T07:42:44Z","timestamp":1390203764000},"page":"1360-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia"],"prefix":"10.1038","volume":"28","author":[{"given":"A","family":"Giannoudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,20]]},"reference":[{"key":"BFleu201438_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2013.04.003","volume":"37","author":"S Francis","year":"2013","unstructured":"Francis S, Lucas C, Lane S, Wang L, Watmough S, Knight K et al. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leuk Res 2013; 37: 752\u2013758.","journal-title":"Leuk Res"},{"key":"BFleu201438_CR2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018\u20131029.","journal-title":"Lancet Oncol"},{"key":"BFleu201438_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/sj.leu.2404692","volume":"21","author":"D Steinbach","year":"2007","unstructured":"Steinbach D, Legrand O . ABC transporters and drug resistance in leukaemia: was P-gp nothing but the first head of the Hydra? Leukaemia 2007; 21: 1172\u20131176.","journal-title":"Leukaemia"},{"key":"BFleu201438_CR4","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 2004; 104: 2940\u20132942.","journal-title":"Blood"},{"key":"BFleu201438_CR5","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohammed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739\u20133745.","journal-title":"Blood"},{"key":"BFleu201438_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important determinant of the response to imatinib in chronic myeloid leukaemia. Clin Pharm Therapeut 2008; 83: 258\u2013264.","journal-title":"Clin Pharm Therapeut"},{"key":"BFleu201438_CR7","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141\u20133148.","journal-title":"Clin Cancer Res"},{"key":"BFleu201438_CR8","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794\u20132799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201438_CR9","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu201438_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ . Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101\u20131108.","journal-title":"Nat Protoc"},{"key":"BFleu201438_CR11","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"NE Jordanides","year":"2006","unstructured":"Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC . Functional ABCG2 is overexpressed on primary CD34+ cells and is inhibiteb by imatinib mesylate. Blood 2006; 108: 1370\u20131373.","journal-title":"Blood"},{"key":"BFleu201438_CR12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-10-0510","volume":"8","author":"A Porro","year":"2011","unstructured":"Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C et al. c-Myc oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myeloid leukemia. Mol Cancer Res 2011; 8: 1054\u20131066.","journal-title":"Mol Cancer Res"},{"key":"BFleu201438_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2210-10-12","volume":"10","author":"L Tang","year":"2010","unstructured":"Tang L, Bergevoet SM, Gilissen C, de Witte T, Jansen JH, van der Reijden BA et al. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol 2010; 10: 1\u20139.","journal-title":"BMC Pharmacol"},{"key":"BFleu201438_CR14","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","volume":"112","author":"A Giannoudis","year":"2008","unstructured":"Giannoudis A, Davies A, Lucas C, Harris RJ, Pirmohamed M, Clark RE . Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112: 3348\u20133354.","journal-title":"Blood"},{"key":"BFleu201438_CR15","doi-asserted-by":"publisher","first-page":"46400","DOI":"10.1074\/jbc.M107041200","volume":"276","author":"N Zelcer","year":"2001","unstructured":"Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P . Characterisation of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276: 46400\u201346407.","journal-title":"J Biol Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201438","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:12:06Z","timestamp":1648743126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,20]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFleu201438"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.38","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,20]]},"assertion":[{"value":"20 January 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}